Related Experiment Video
Updated: Jul 11, 2025
11:15
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
8.0K
Targeting immunogenic cell death for glioma immunotherapy
Tatiana A Mishchenko1, Victoria D Turubanova2, Ekaterina N Gorshkova1
1Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
Trends in Cancer
|November 16, 2023
Summary
Immunogenic cell death (ICD) can boost immunotherapy for glioma. Unexpectedly, ICD also induces Th17 immunity, paving the way for novel dendritic cell (DC)-based glioma vaccines.
Area of Science:
- Immunology
- Oncology
- Neuroscience
Background:
- Glioma is the most common primary brain tumor.
- Immunotherapy aims to enhance the immune response against cancer.
- Immunogenic cell death (ICD) is a promising strategy to stimulate anti-tumor immunity.
Purpose of the Study:
- To explore the potential of ICD in targeting glioma.
- To investigate the induction of Th17 immunity by ICD.
- To propose an optimized design for dendritic cell (DC)-based glioma vaccines.
Main Methods:
- Utilizing ICD inducers to treat glioma.
- Analyzing the immune response, focusing on Th17 cells.
- Developing DC-based vaccines loaded with ICD-generated glioma lysates.
Main Results:
- Unexpected induction of Th17 immunity by ICD in the context of glioma.
- Demonstrated potential for enhanced immunotherapy through ICD.
Conclusions:
- ICD can be a valuable strategy for glioma treatment.
- The induction of Th17 immunity by ICD offers new avenues for vaccine development.
- Optimized DC-based vaccines loaded with ICD-glioma lysates hold promise for future glioma immunotherapy.
